| Identification | Back Directory | [Name]
1-PropanesulfonaMide, N-[3-[(5-broMo-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]- | [CAS]
918504-27-5 | [Synonyms]
N-(3-(5-broMo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl)propane-1-sulfonaMide N-[3-[(5-Bromo-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide 1-PropanesulfonaMide, N-[3-[(5-broMo-1H-pyrrolo[2,3-b]pyridin-3-yl)carbonyl]-2,4-difluorophenyl]- Propane-1-sulfonic acid [3-(5-bromo-1H-pyrrolo[2,3-b]pyridine-3-carbonyl)-2,4-difluorophenyl]amide, | [EINECS(EC#)]
806-749-7 | [Molecular Formula]
C17H14BrF2N3O3S | [MDL Number]
MFCD18207768 | [MOL File]
918504-27-5.mol | [Molecular Weight]
458.28 |
| Chemical Properties | Back Directory | [density ]
1.689±0.06 g/cm3(Predicted) | [storage temp. ]
Sealed in dry,2-8°C | [form ]
Solid | [pka]
6.19±0.10(Predicted) | [color ]
Off-white to light yellow |
| Hazard Information | Back Directory | [Uses]
B-Raf IN 11 (ZINC72115182) is a selective B-RafV600E inhibitor (IC50=76 nM), shows selectivity for
B-RafV600E over B-RafWT with selectivity of 3.1-fold. B-Raf IN 11 can be used in colorectal cancer research[1] | [Synthesis]
General method: 2,6-Difluoro-3-(propylsulfonamido)benzoic acid (1.1 eq.) was suspended in anhydrous dichloromethane (DCM, 0.5 M), oxalyl chloride (1.05 eq.) and a catalytic amount of N,N-dimethylformamide (DMF, a few drops) were added sequentially. The reaction mixture was stirred at room temperature until gas release ceased. Subsequently, the resulting chloride solution was slowly added dropwise to a suspension of anhydrous DCM (0.5 M) containing 5-bromo-7-azaindole (1 eq.) and anhydrous aluminum trichloride (AlCl3, 5 eq.). The reaction mixture was continued to be stirred at room temperature for 0.5 to 3 hours. Upon completion of the reaction, saturated aqueous ammonium chloride (NH4Cl) was added to quench the reaction. The aqueous phase was extracted with ethyl acetate (EtOAc, 3 times) and the combined organic layers were dried over anhydrous sodium sulfate (Na2SO4) and concentrated under reduced pressure to remove the solvent. The crude product was purified by fast column chromatography using silica gel (SiO2) as stationary phase and n-hexane/ethyl acetate (1:1, v/v) or dichloromethane/methanol (the methanol content was increased in a gradient from 0.5% to 5%, and ultimately did not exceed 3%, v/v) to afford the target compound N-[3-[(5-bromo-1H-pyrrolo[2,3-b]pyridin-3-yl) carbonyl]-2,4-difluorophenyl]-1-propanesulfonamide. | [IC 50]
B-RafV600E: 76 nM (IC50); BRAFWT: 238 nM (IC50) | [References]
[1] Yao H, et al. Identification and Characterization of Small-Molecule Inhibitors to Selectively Target the DFG-in over the DFG-out Conformation of the B-Raf Kinase V600E Mutant in Colorectal Cancer. Arch Pharm (Weinheim). 2016 Oct;349(10):808-815. DOI:10.1002/ardp.201600184 |
|
| Company Name: |
Cool Pharm, Ltd
|
| Tel: |
021-60455363 18019463053 |
| Website: |
www.coolpharm.com |
| Company Name: |
NovoChemy Ltd.
|
| Tel: |
86-(0)21-31261262 373522135 |
| Website: |
www.novochemy.com |
|